Can we advise ovulation induction in patients with SLE?

References

• Mintz G, Niz J, Guttierez G, Garcia-Alonso A, Karchmer S. Prospective study of pregnancy in systemic in systemic lupus erythematosus: results of a multidisciplinary approach. J Rheumatol 1986; 13:732–9.
   PubMed Web of Science ®Google Scholar
• Lê Thi Huong D, Wechsler B, Vauthier-Brouzes D, See- bacher J, Lefèbvre G, Blétry O, et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol 1997; 36:772–7.
   PubMedGoogle Scholar
• Petri M, Howard D, Repke J, Goldman DW. The Hopkins Lupus Pregnancy Center: 1987–1991 update. Am J Reprod Immunol 1992; 28:188–91.
   PubMed Web of Science ®Google Scholar
• Kitridou RC, Mintz G. Pregnancy in Lupus: The mother in SLE. Dubois Lupus Erythematosus. Wallace DJ and Hahn BH Eds. 4th Ed. Lea and Fibiger Philadelphia 1993; 487–507.
   Google Scholar
• Thonneau P, Marchand S, Tallec S. Incidence and main causes of infertility in a resident population (1850000) of three french regions (1988–1989). Hum Reprod 1991; 6:811–6.
   Google Scholar
• Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41:831–7.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenonhea i patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119:366–9.
   PubMed Web of Science ®Google Scholar
• McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55:224–9.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Laskin CA. Sex hormones in systemic lupus erythematosus: a controversy for modern times. J Rheumatol 1997; 24:1461–3.
   PubMed Web of Science ®Google Scholar
• Case records of the Massachusetts general hospital. N Engl J Med 1986; 315:1336–43.
   PubMedGoogle Scholar
• Piette JC, Le Thi Huong D, Papo T. Postmenopausal hormone therapy and systemic lupus erythematosus. Ann Intern Med 1995; 123:961–2.
   PubMedGoogle Scholar
• Balasch J, Creus M, Fabregues F, Reverter JC, Cannona F. Tassies D, et al. Antiphospholipid antibodies and human reproductive failure. Human Reprod 1996; 11:2310–5.
   PubMed Web of Science ®Google Scholar
• Birdsall MA, Lockwood GM, Ledger WL. Johnson PM, Chamley LW. Antiphospholipid antibodies in women having in vitro fertilization. Hum Reprod 1996: 11:1185–9.
   PubMed Web of Science ®Google Scholar
• Kowalik A, Vichnin M, Liu HC, Branch W, Berkeley AS. Midfollicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome. Fertil Steril 1997; 68:298–304.
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Yetman DL, Chantilis SJ, Crain J. Effect of antiphospholipid antibodies in women undergoing in vitro fertilization: Role of heparin. Hum Reprod 1997: 12:1171–5.
   PubMed Web of Science ®Google Scholar
• Sher G, Feinman M. Zouves C, Kuttner G. Massarani G, Salem R, et al. High fecundity rates following in vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994; 9:2278–83.
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Mozes E, Tartakovsky B. Anticardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA 1993: 90:6464–7.
   PubMed Web of Science ®Google Scholar
• Meirow D, Laufer N, Schenker JG. Ovulation and in vitro fertilization. Gynecol Endocrinol 1993; 6:211–24.
   Web of Science ®Google Scholar
• Ben-Chetrit A, Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum 1994; 37:1614–7.
   PubMed Web of Science ®Google Scholar
• Casoli P, Tumiati B, La Sala G. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 1997; 24:1639–40.
   PubMed Web of Science ®Google Scholar
• Le Thi Huong D, Wechsler B, Piette JC. Arfi S, Gallinari C, Darbois Y, et al. Risk of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 1996; 35:1184–6.
   PubMedGoogle Scholar
• Miyagawa S, Shirai T, Shimamoto I. Ichijo M. Ueki H. Worsening of systemic lupus erythematosus-associated thrombocytopenia after administration of gonadotropin-releasing hormone analog. Arthritis Rheum 1994; 37:1708–9.
   PubMed Web of Science ®Google Scholar
• Schencker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978: 30:255–68.
   PubMed Web of Science ®Google Scholar
• Simon A, Revel A, Hurwitz A, Laufer N. The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma. J Assist Reprod Genet 1998; 15:202–9.
   PubMed Web of Science ®Google Scholar
• Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome: view and ideas. Hum Reprod 1997; 12:1129–37.
   PubMed Web of Science ®Google Scholar
• De Jong D, Macklon NS, Mannaerts BM, Coclingh Bennink HJ, Fauser BC. High dose gonadotrophin-releasing hormone antagonist (garinelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in vitro fertilization. Hum Reprod 1998; 13:573–5.
   PubMed Web of Science ®Google Scholar
• Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996; 11:1381–6.
   PubMed Web of Science ®Google Scholar
• Krasnow JS, Berga SL, Gusik DS, Zeleznik AJ, Yeo KT. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 1996; 65:552–5.
   PubMed Web of Science ®Google Scholar
• Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate with the clinical picture in severe ovarian hyperstimulation syndrone. Fertil Steril 1997; 67:261–5.
   PubMed Web of Science ®Google Scholar
• Mathur RS, Jenkins JM, Bansal AS. The possible role of the immune system in the aethiopathogenesis of ovarian hyperstimulation syndrome. Human reprod 1997; 12:2629–34.
   PubMed Web of Science ®Google Scholar
• Amoura Z, Papo T, Ninet J, Hatron PY, Guillaumie J, Piette AM, et al. Systemic capillary leak syndrome: Report on 13 patients with special focus on course and treatment. Am J Med 1997; 103:514–9.
   PubMed Web of Science ®Google Scholar
• Stewart JA, Hamilton PJ, Murdoch AP. Upper limb thrombosis associated with assisted conception treatment. Human Reprod 1997; 12:2174–5.
   PubMed Web of Science ®Google Scholar
• Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Human Reprod 1997; 12:2167–73.
   PubMed Web of Science ®Google Scholar
• Vauthier-Brouzes D, Lefebvre G, Seebacher J, Wechsler B. Thrombose veineuse jugulaire interne en cours de grossesse après hyperstimulation ovarienne pour FIV. Contracept Fertil Sex 1993; 21:33–5.
   PubMedGoogle Scholar
• Douketis JD, Ginsberg J, Ginsberg JS, Holbrook A, Pharm D, Crowther M, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormonal replacement therapy. Arch Intern Med 1997; 157:1552–9.
   Google Scholar
• Aune B, Hoie KE, Oian P, Hoist N, Osterud B. Does ovarian hyperstimulation for in vitro fertilization induce a hypercoagulable state? Hum Reprod 1991; 6:925–7.
   PubMed Web of Science ®Google Scholar
• Ellis MH, Ben Nun I, Rathaus V, Wermer M, Shenkman L. Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome. Fertil Steril 1988; 69:140–2.
   Web of Science ®Google Scholar
• Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 1989; 32:665–70.
   PubMed Web of Science ®Google Scholar
• Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum 1991; 34:1538–45.
   PubMed Web of Science ®Google Scholar
• Le Thi Huong D, Wechsler B, Piette JC, Blétry O, Godeau P. Pregnancy and its outcome in systemic lupus erythematosus. QJ Med 1994; 87:721–9.
   Google Scholar
• Tan SL, Balen A, Hussein E, Campbell S, Jacobs HS. The use of glucocorticcoids for the prevention of ovarian hyperstimulation syndrome: a prospective randomised study. Fertil Steril 1992; 58:378–83.
   PubMed Web of Science ®Google Scholar
• Graf MA, Fisher R, Naether OG, Baukloh V, Tafel J, Nuckel M. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in vitro fertilization programme. Hum Reprod 1997;12:2599–2602.
   PubMed Web of Science ®Google Scholar
• Le Thi Huong D, Wechsler B, Edelman P, Pournie A, Le Tallec Y, Piette JC, et al. Postpartum cerebral infarction associated with aspirin withdrawal in the antiphospholid antibody syndrome. J Rheumatol 1993; 30:1229–32.
   Google Scholar
• Amout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin- induced thrombocytopenia. Thromb Haemos 1996; 75:536–41.
   PubMed Web of Science ®Google Scholar
• Lasne D, Saffroy R, Bachelot A, Rendu F, Papo T, et al. Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome. Br J Haematol 1997; 97:939.
   PubMed Web of Science ®Google Scholar